中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 3
Mar.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(3): 688-692

Mechanism of action and clinical significance of hypoxia-inducible factors in hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2022.03.040
  • 1.

    Key Laboratory of Applied Basic Research of Guangxi Zhuang Medicine, Guangxi University of Chinese Medicine, Nanning 530200, China

  • 2.

    Department of Medicine, Hubei Minzu University, Enshi, Hubei 445000, China

Research funding:

Guangxi Medical High Level Backbone Personnel Training "139" Program Funding Project (GWKJF〔2020〕No.15);

Key Laboratory of Applied Basic Research of Zhuang Medicine of Guangxi Health Committee (Guangxi University of traditional Chinese Medicine) (GWKJF〔2020〕No.17);

"Qi Huang Project" High Level Talent Team Cultivation Project of Guangxi University of Traditional Chinese Medicine (2021003);

Guangxi First Class Discipline of Traditional Chinese Medicine (GJKS〔2018〕No.12)

More Information
  • Corresponding author: PANG Yuzhou, pangyz422@sina.com(ORCID: 0000-0003-4410-5050)
  • Received Date: 2021-07-22
  • Accepted Date: 2021-08-12
  • Published Date: 2022-03-20
    Abstract
  • Due to the rapid proliferation and growth of tumor cells, hypoxic microenvironment exists in many solid tumors, and hypoxia inducible factors (HIF) are critical for sensing oxygen tension within tumors and subsequently mediating the activation of hypoxia responses. Hepatocellular carcinoma (HCC) is one of the most hypoxic tumors. This article summarizes the mechanism of action of HIF in promoting the development and progression of HCC by promoting glycolysis, angiogenesis, invasion and metastasis, immune escape, and cancer stem cell formation. At present, the development of targeted drugs for HIF inhibitors has broad prospects in the treatment of HCC, and the detection of HIF also has a potential value in prognostic evaluation HCC.

     

    • FullText(HTML)
  • loading
    • References(51)
  • [1]
    VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462. DOI: 10.1056/NEJMra1713263.
    [2]
    GIGANTE E, PARADIS V, RONOT M, et al. New insights into the pathophysiology and clinical care of rare primary liver cancers[J]. JHEP Rep, 2021, 3(1): 100174. DOI: 10.1016/j.jhepr.2020.100174.
    [3]
    YUEN VW, WONG CC. Hypoxia-inducible factors and innate immunity in liver cancer[J]. J Clin Invest, 2020, 130(10): 5052-5062. DOI: 10.1172/JCI137553.
    [4]
    MÉNDEZ-BLANCO C, FERNÁNDEZ-PALANCA P, FONDEVILA F, et al. Prognostic and clinicopathological significance of hypoxia-inducible factors 1α and 2α in hepatocellular carcinoma: A systematic review with meta-analysis[J]. Ther Adv Med Oncol, 2021, 13: 1758835920987071. DOI: 10.1177/1758835920987071.
    [5]
    ZHANG Y, COLEMAN M, BREKKEN RA. Perspectives on hypoxia signaling in tumor stroma[J]. Cancers (Basel), 2021, 13(12): 3070. DOI: 10.3390/cancers13123070.
    [6]
    KOU HB, HAN DB, FAN YS, et al. Expression and clinical significance of hypoxia-inducible factor 1 α and E-cadherin in renal clear cell carcinoma[J]. Clin J Med Offic, 2020, 48(6): 649-652. DOI: 10.16680/j.1671-3826.2020.06.09.

    寇宏博, 韩冬冰, 范以生, 等. 缺氧诱导因子1α、上皮钙粘附蛋白在肾透明细胞癌中表达及临床意义[J]. 临床军医杂志, 2020, 48(6): 649-652. DOI: 10.16680/j.1671-3826.2020.06.09.
    [7]
    MYLONIS I, SIMOS G, PARASKEVA E. Hypoxia-inducible factors and the regulation of lipid metabolism[J]. Cells, 2019, 8(3): 214. DOI: 10.3390/cells8030214.
    [8]
    PASCALE RM, CALVISI DF, SIMILE MM, et al. The warburg effect 97 years after its discovery[J]. Cancers (Basel), 2020, 12(10): 2819. DOI: 10.3390/cancers12102819.
    [9]
    DONG F, LI R, WANG J, et al. Hypoxia-dependent expression of MAP17 coordinates the Warburg effect to tumor growth in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2021, 40(1): 121. DOI: 10.1186/s13046-021-01927-5.
    [10]
    PATEL MS, MAHMOOD S, JUNG J, et al. Reprogramming of aerobic glycolysis in non-transformed mouse liver with pyruvate dehydrogenase complex deficiency[J]. Physiol Rep, 2021, 9(1): e14684. DOI: 10.14814/phy2.14684.
    [11]
    ZHANG MY, ZHANG RJ, JIANG HJ, et al. 18F-fluoromisonidazole positron emission tomography may be applicable in the evaluation of colorectal cancer liver metastasis[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(2): 164-172. DOI: 10.1016/j.hbpd.2019.02.008.
    [12]
    SONG HS, SONG YH, SINGH N, et al. New self-assembled supramolecular bowls as potent anticancer agents for human hepatocellular carcinoma[J]. Sci Rep, 2019, 9(1): 242. DOI: 10.1038/s41598-018-36755-9.
    [13]
    CHEN J, CHEN J, HUANG J, et al. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway[J]. Aging (Albany NY), 2019, 11(23): 10839-10860. DOI: 10.18632/aging.102488.
    [14]
    JIANG XL, LI YC, JIANG XC, et al. HIF-mediated DEPTOR participates in the invasion and angiogenesis of liver cancer HepG2 cells through the PDCD4c-Jun(AP-1) signaling pathway[J]. J Clin Exp Med, 2020, 19(23): 2498-2501. DOI: 10.3969/j.issn.1671-4695.2020.23.010.

    蒋小丽, 李阳超, 蒋叙川, 等. HIF介导的DEPTOR通过PDCD4c-Jun(AP-1)信号通路参与肝癌HepG2细胞侵袭和血管生成研究[J]. 临床和实验医学杂志, 2020, 19(23): 2498-2501. DOI: 10.3969/j.issn.1671-4695.2020.23.010.
    [15]
    WU L, ZHOU J, ZHOU W, et al. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo[J]. Pathol Res Pract, 2021, 220: 153270. DOI: 10.1016/j.prp.2020.153270.
    [16]
    YU J, SHI X, YANG C, et al. A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia[J]. Aging (Albany NY), 2020, 12(7): 5781-5791. DOI: 10.18632/aging.102967.
    [17]
    MARIOTTI V, FIOROTTO R, CADAMURO M, et al. New insights on the role of vascular endothelial growth factor in biliary pathophysiology[J]. JHEP Rep, 2021, 3(3): 100251. DOI: 10.1016/j.jhepr.2021.100251.
    [18]
    WEI X, ZHAO L, REN R, et al. MiR-125b loss activated HIF1α/pAKT loop, leading to transarterial chemoembolization resistance in hepatocellular carcinoma[J]. Hepatology, 2021, 73(4): 1381-1398. DOI: 10.1002/hep.31448.
    [19]
    YANG B, PAN CS, LI Q, et al. Inhibitory effects of Chanling Gao on the proliferation and liver metastasis of transplanted colorectal cancer in nude mice[J]. PLoS One, 2019, 14(2): e0201504. DOI: 10.1371/journal.pone.0201504.
    [20]
    HE Y, YANG W, GAN L, et al. Silencing HIF-1α aggravates non-alcoholic fatty liver disease in vitro through inhibiting PPAR-α/ANGPTL4 singling pathway[J]. Gastroenterol Hepatol, 2021, 44(5): 355-365. DOI: 10.1016/j.gastrohep.2020.09.014.
    [21]
    TIRPE AA, GULEI D, CIORTEA SM, et al. Hypoxia: Overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes[J]. Int J Mol Sci, 2019, 20(24): 6140. DOI: 10.3390/ijms20246140.
    [22]
    GURZU S, KOBORI L, FODOR D, et al. Epithelial mesenchymal and endothelial mesenchymal transitions in hepatocellular carcinoma: A review[J]. Biomed Res Int, 2019, 2019: 2962580. DOI: 10.1155/2019/2962580.
    [23]
    KHALAF K, HANA D, CHOU JT, et al. Aspects of the tumor microenvironment involved in immune resistance and drug resistance[J]. Front Immunol, 2021, 12: 656364. DOI: 10.3389/fimmu.2021.656364.
    [24]
    TAKEMOTO R, KAMIYA T, ATOBE T, et al. Regulation of lysyl oxidase expression in THP-1 cell-derived M2-like macrophages[J]. J Cell Biochem, 2021, 122(8): 777-786. DOI: 10.1002/jcb.29911.
    [25]
    LIU Y, TAN J, OU S, et al. Adipose-derived exosomes deliver miR-23a/b to regulate tumor growth in hepatocellular cancer by targeting the VHL/HIF axis[J]. J Physiol Biochem, 2019, 75(3): 391-401. DOI: 10.1007/s13105-019-00692-6.
    [26]
    CHEN Y, HUANG F, DENG L, et al. HIF-1-miR-219-SMC4 regulatory pathway promoting proliferation and migration of HCC under hypoxic condition[J]. Biomed Res Int, 2019, 2019: 8983704. DOI: 10.1155/2019/8983704.
    [27]
    DOU C, ZHOU Z, XU Q, et al. Hypoxia-induced TUFT1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca2+/PI3K/AKT pathway[J]. Oncogene, 2019, 38(8): 1239-1255. DOI: 10.1038/s41388-018-0505-8.
    [28]
    SONG Y, JIN X, LIU Y, et al. Long noncoding RNA ZFPM2-AS1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by regulating the miR-576-3p/HIF-1α axis[J]. Anticancer Drugs, 2021, 32(8): 812-821. DOI: 10.1097/CAD.0000000000001070.
    [29]
    YE Y, PENG Y, LI Y, et al. Effect of lincRNA-p21 targeting HIF-1α on biological functions of liver cancer cells[J]. Oncol Lett, 2019, 17(6): 4964-4968. DOI: 10.3892/ol.2019.10195.
    [30]
    CUI C, FU K, YANG L, et al. Hypoxia-inducible gene 2 promotes the immune escape of hepatocellular carcinoma from nature killer cells through the interleukin-10-STAT3 signaling pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 229. DOI: 10.1186/s13046-019-1233-9.
    [31]
    PIÑEIRO FERNÁNDEZ J, LUDDY KA, HARMON C, et al. Hepatic tumor microenvironments and effects on NK cell phenotype and function[J]. Int J Mol Sci, 2019, 20(17): 4131. DOI: 10.3390/ijms20174131.
    [32]
    WU Q, ZHOU W, YIN S, et al. Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer[J]. Hepatology, 2019, 70(1): 198-214. DOI: 10.1002/hep.30593.
    [33]
    WEN Q, HAN T, WANG Z, et al. Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape[J]. Oncol Lett, 2020, 19(4): 2595-2601. DOI: 10.3892/ol.2020.11369.
    [34]
    HAJIZADEH F, OKOYE I, ESMAILY M, et al. Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells[J]. Life Sci, 2019, 237: 116952. DOI: 10.1016/j.lfs.2019.116952.
    [35]
    SUN X, LV X, YAN Y, et al. Hypoxia-mediated cancer stem cell resistance and targeted therapy[J]. Biomed Pharmacother, 2020, 130: 110623. DOI: 10.1016/j.biopha.2020.110623.
    [36]
    AKANJI MA, ROTIMI D, ADEYEMI OS. Hypoxia-inducible factors as an alternative source of treatment strategy for cancer[J]. Oxid Med Cell Longev, 2019, 2019: 8547846. DOI: 10.1155/2019/8547846.
    [37]
    LI Y, GUO P, TIAN YY. Effects of Huangqin Decoction combined with sequential hepatic arterial chemoembolization on the expression of NF-κB and HIF-1α in patients with primary liver cancer[J]. China J Tradit Chin Med Pharma, 2019, 34(8): 3870-3873. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201908146.htm

    李岩, 郭鹏, 田月洋. 黄芩汤联合序贯肝动脉化疗栓塞术对原发性肝癌患者核因子κB及细胞缺氧诱导因子-1α的影响[J]. 中华中医药杂志, 2019, 34(8): 3870-3873. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201908146.htm
    [38]
    张健, 彭勇, 马海, 等. 水飞蓟素对缺氧人肝癌HepG-2细胞HIF-1α及MDR1表达的影响[J/CD]. 肿瘤代谢与营养电子杂志, 2021, 8(2): 175-178. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLDX202102016.htm
    [39]
    LIANG C, DONG Z, CAI X, et al. Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma[J]. Cell Death Dis, 2020, 11(11): 1017. DOI: 10.1038/s41419-020-03233-y.
    [40]
    FENG J, DAI W, MAO Y, et al. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis[J]. J Exp Clin Cancer Res, 2020, 39(1): 24. DOI: 10.1186/s13046-020-1528-x.
    [41]
    ZHAO JJ, ZHANG HG, CUI FF, et al. Effect of hypoxia-inducible factor-1α on stemness and epirubicin sensitivity of HepG2 hepatoma cells[J]. J Clin Hepatol, 2021, 37(2): 354-357. DOI: 10.3969/j.issn.1001-5256.2021.02.021.

    赵金金, 张海光, 崔非非, 等. 缺氧诱导因子1α对肝癌细胞HepG2干细胞特性及表阿霉素敏感性的影响[J]. 临床肝胆病杂志, 2021, 37(2): 354-357. DOI: 10.3969/j.issn.1001-5256.2021.02.021.
    [42]
    JU C, COLGAN SP, ELTZSCHIG HK. Hypoxia-inducible factors as molecular targets for liver diseases[J]. J Mol Med (Berl), 2016, 94(6): 613-627. DOI: 10.1007/s00109-016-1408-1.
    [43]
    DENG F, CHEN D, WEI X, et al. Development and validation of a prognostic classifier based on HIF-1 signaling for hepatocellular carcinoma[J]. Aging (Albany NY), 2020, 12(4): 3431-3450. DOI: 10.18632/aging.102820.
    [44]
    WANG D, LU S, ZHANG X, et al. Co-expression of KIAA1199 and hypoxia-inducible factor 1α is a biomarker for an unfavorable prognosis in hepatocellular carcinoma[J]. Medicine (Baltimore), 2020, 99(50): e23369. DOI: 10.1097/MD.0000000000023369.
    [45]
    LI Q, NI Y, ZHANG L, et al. HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation[J]. Signal Transduct Target Ther, 2021, 6(1): 76. DOI: 10.1038/s41392-020-00453-8.
    [46]
    FANG X, ZHANG D, ZHAO W, et al. Dishevelled associated activator of morphogenesis (DAAM) facilitates invasion of hepatocellular carcinoma by upregulating hypoxia-inducible factor 1α (HIF-1α) expression[J]. Med Sci Monit, 2020, 26: e924670. DOI: 10.12659/MSM.924670.
    [47]
    QIAN Y, LI Y, ZHENG C, et al. High methylation levels of histone H3 lysine 9 associated with activation of hypoxia-inducible factor 1α (HIF-1α) predict patients' worse prognosis in human hepatocellular carcinomas[J]. Cancer Genet, 2020, 245: 17-26. DOI: 10.1016/j.cancergen.2020.04.077.
    [48]
    JIANG Z, ZHOU Q, GE C, et al. Rpn10 promotes tumor progression by regulating hypoxia-inducible factor 1 alpha through the PTEN/Akt signaling pathway in hepatocellular carcinoma[J]. Cancer Lett, 2019, 447: 1-11. DOI: 10.1016/j.canlet.2019.01.020.
    [49]
    HIROTA K. An intimate crosstalk between iron homeostasis and oxygen metabolism regulated by the hypoxia-inducible factors (HIFs)[J]. Free Radic Biol Med, 2019, 133: 118-129. DOI: 10.1016/j.freeradbiomed.2018.07.018.
    [50]
    GUO Y, XIAO Z, YANG L, et al. Hypoxia?inducible factors in hepatocellular carcinoma (Review)[J]. Oncol Rep, 2020, 43(1): 3-15. DOI: 10.3892/or.2019.7397.
    [51]
    WANG P, YAN Q, LIAO B, et al. The HIF1α/HIF2α-miR210-3p network regulates glioblastoma cell proliferation, dedifferentiation and chemoresistance through EGF under hypoxic conditions[J]. Cell Death Dis, 2020, 11(11): 992. DOI: 10.1038/s41419-020-03150-0.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (621) PDF downloads(34) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return